PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML

被引：0
|
作者：
Kadia, T. [1 ]
Cortes, J. [1 ]
Borthakur, G. [1 ]
Jabbour, E. [1 ]
Daver, N. [1 ]
Pemmaraju, N. [1 ]
Verstovsek, S. [1 ]
Burger, J. [1 ]
Ferrajoli, A. [1 ]
Wierda, W. [1 ]
Konopleva, M. [1 ]
DiNardo, C. [1 ]
Jain, N. [1 ]
Brandt, M. [1 ]
Tuttle, C. [1 ]
Wang, X. [1 ]
Ravandi, F. [1 ]
Garcia-Manero, G. [1 ]
Kantarjian, H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P187
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [41] A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas.
    Dumont, S. N.
    Trent, J. C.
    Patel, S.
    Araujo, D. M.
    Dumont, A. G.
    Benjamin, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Low-dose Fotemustine in elderly patients with recurrent glioblastoma: A phase II prospective study
    Bellu, L.
    Lombardi, G.
    Pambuku, A.
    Bergo, E.
    Zagonel, V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S591 - S591
  • [43] Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome
    Montero, Alberto J.
    Estrov, Zeev
    Freireich, Emil J.
    Khouri, Issa F.
    Koller, Charles A.
    Kurzrock, Razelle
    LEUKEMIA & LYMPHOMA, 2006, 47 (10) : 2049 - 2054
  • [44] Venetoclax Combined with Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Cortes, Jorge E.
    Konopleva, Marina Y.
    Borthakur, Gautam M.
    Pemmaraju, Naveen
    Daver, Naval G.
    Bravo, Guillermo Montalban
    Issa, Ghayas C.
    Naqvi, Kiran
    Short, Nicholas J.
    DiNardo, Courtney D.
    Bhalla, Kapil N.
    Jabbour, Elias
    Takahashi, Koichi
    Sasaki, Koji
    Kornblau, Steven M.
    Malla, Rashmi
    Pierce, Sherry A.
    Wang, Xuemei
    Estrov, Zeev E.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [45] A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis
    Lin, Chenyu
    Patel, Anand A.
    Huo, Dezheng
    Karrison, Theodore
    van Besien, Koen
    Godwin, John
    Sher, Dorie
    Weiner, Howie
    Green, Margaret
    Wade III, James L.
    Klisovic, Rebecca
    Baer, Maria R.
    Larson, Richard A.
    Stock, Wendy
    Odenike, Olatoyosi
    BLOOD ADVANCES, 2024, 8 (22) : 5735 - 5743
  • [46] Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles
    Kantarjian, Hagop M.
    Begna, Kebede H.
    Altman, Jessica K.
    Goldberg, Stuart L.
    Sekeres, Mikkael A.
    Strickland, Stephen A.
    Rubenstein, Stephen E.
    Arellano, Martha L.
    Claxton, David F.
    Baer, Maria R.
    Gautier, Marc
    Berman, Ellin
    Seiter, Karen
    Solomon, Scott R.
    Schiller, Gary J.
    Luger, Selina
    Butrym, Aleksandra
    Gaidano, Gianluca
    Thomas, Xavier
    Montesinos, Pau
    Rizzieri, David A.
    Quick, Donald P.
    Agura, Edward
    Venugopal, Parameswaran
    Subramanian, Janakiraman
    Maness, Lori J.
    Robert, Daniel-Eric
    Hicheri, Yosr
    Kadia, Tapan
    Ravandi, Farhad
    Buyse, Marc E.
    Chiao, Judy
    BLOOD, 2017, 130
  • [47] A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML
    Levitz, David
    Fedorov, Kate
    Goldfinger, Mendel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S282 - S283
  • [48] Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies.
    Wang, Chunmeng
    Liu, Yang
    Zhang, Wenying
    Chen, Meixia
    Shi, Lu
    Dong, Liang
    Li, Xiang
    Yang, Qingming
    Nie, Jing
    Han, WeiDong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [50] A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients.
    Wijermans, P
    Lübbert, M
    Verhoef, G
    Bosly, A
    Ravoet, C
    Andre, M
    Ferrant, A
    BLOOD, 1998, 92 (10) : 632A - 632A
12345